Cited by 31Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNerve injury and regeneration

Increased Expression of TrkB and Capzb2 Accompanies Preserved Cognitive Status in Early Alzheimer Disease Pathology

Open access
Kao, Patricia F., Banigan, Meredith G., Vanderburg, Charles R., McKee, Ann C., Polgar, Peter R., Seshadri, Sudha, Delalle, Ivana·2012·Journal of Neuropathology & Experimental Neurology

Abstract

Brain-derived neurotrophic factor (BDNF) and its receptor tyrosine kinase B (TrkB) may influence brain reserve, the ability of the brain to tolerate pathological changes without significant decline in function. Here, we explore whether a specifically vulnerable population of human neurons shows a compensatory response to the neuropathological changes of Alzheimer disease (AD) and whether that response depends on an upregulation of the BDNF pathway. We observed increased neuronal TrkB expression associated with early-stage AD pathology (Braak and Braak stages I-II) in hippocampal CA1 region samples from cognitively intact Framingham Heart Study subjects (n = 5) when compared with cognitively intact individuals with no neurofibrillary tangles (n = 4). Because BDNF/TrkB signaling affects memory formation and retention through modification of the actin cytoskeleton, we examined the expression of actin capping protein β2 (Capzb2), a marker of actin cytoskeleton reorganization. Capzb2 expression was also significantly increased in CA1 hippocampal neurons of cognitively intact subjects with early-stage AD pathology. Our data suggest that increased expression of TrkB and Capzb2 accompanies adequate brain reserve in the initial stages of AD pathology. In subsequent stages of AD, the higher levels of TrkB and Capzb2 expression achieved may not be sufficient to prevent cognitive decline.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e31825d06b7

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Serum BDNF parallels relative difference in BDNF levels, but BDNF levels may be substantially higher, have attenuated effects over time, and may be subject to variability because of differences in expression levels of BDNF receptors.

    “Although serum BDNF parallels relative difference in BDNF levels, BDNF levels may be substantially higher, have attenuated effects over time, and may be subject to variability of effect because of differences in the expression levels of BDNF receptors [8].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kao, P. F., Banigan, M. G., Vanderburg, C. R., McKee, A. C., Polgar, P. R., Seshadri, S., & Delalle, I.
Affiliations
  • Boston University (US)
  • Harvard University (US)
Corresponding author
Delalle, Ivana
Venue
Journal of Neuropathology & Experimental Neurology
Published
2012-07
Volume
71
Issue
7
Pages
654-664
ISSN
0022-3069 (ISSN-L)
OpenAlex
W2023092508
Cited by
31
References
53
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2021: 2 · 2020: 3 · 2019: 1 · 2017: 8 · 2016: 5 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 1
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuropathology & Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5t32ag000115-25)
  • National Institute on Aging (R01AG031287, T32-AG-000115, 5T32AG000115-25, R01AG016495, P30AG013846, R01AG033193, R01AG008122)
  • National Institute of Neurological Disorders and Stroke (R01NS017950)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
Alzheimer's disease, TrkB, brain-derived neurotrophic factor, brain reserve, CA1 pyramidal neurons, neurofibrillary tangles, Braak stages, actin cytoskeleton, cognitive preservation, Framingham Heart Study
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Dementia, Female, Hippocampus, Humans, Male, Neuropsychological Tests, RNA, Messenger, Signal Transduction, Up-Regulation, Silver Staining, Brain-Derived Neurotrophic Factor, Receptor, trkB, Actin Capping Proteins, Laser Capture Microdissection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review